HCPLive

Data Suggest Depression Doesn't Precede Impaired Cognition

 
MONDAY, Jan. 7 (HealthDay News) -- Among older adults, depression correlates with prevalent mild cognitive impairment (MCI) and progression to dementia, but not with incident MCI, according to a study published online Dec. 31 in JAMA Neurology.

To examine the correlation of late-life depression with MCI and dementia, Edo Richard, M.D., Ph.D., from the University of Amsterdam, and colleagues conducted a cohort study involving 2,160 community-dwelling Medicare recipients, aged 65 years or older, from New York City.

The researchers found that the likelihood of prevalent MCI (odds ratio, 1.4) and dementia (odds ratio, 2.2) were significantly elevated with baseline depression. Depression at baseline correlated with a significantly elevated risk of incident dementia (hazard ratio [HR], 1.7), but not incident MCI (HR, 0.9; 95 percent confidence interval, 0.7 to 1.2). The risk of progression to dementia, especially vascular dementia, but not Alzheimer's disease, was elevated for those with MCI and coexisting depression at baseline (HR, 2.0 for dementia and 4.3 for vascular dementia).

"The association of depression with prevalent MCI and with progression from MCI to dementia, but not with incident MCI, suggests that depression accompanies cognitive impairment but does not precede it," the authors write.
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

Tenofovir alafenamide, which results in 90% lower circulating plasma tenofovir than standard tenofovir disoproxil fumarate, is associated with similar virologic response rates as the standard regimen, but with an improved safety profile.
Combination treatment with daclatasvir and asunaprevir plus interferon/ribavirin had high success rates in a 24-week clinical trial for treatment of hepatitis C in patients coninfected with HIV.
An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.
Novel second-generation HIV-1 maturation inhibitor shows favorable antiviral activity and safety profile in HIV-1, subtype B-infected subjects
$vAR$